U.S. Markets closed

Wired News – Alkermes Gets License Payment from Biogen Following Review of Preliminary Gastrointestinal Tolerability Data of BIIB098 for Multiple Sclerosis Treatment

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Alkermes PLC (NASDAQ: ALKS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALKS as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has received a $50 million payment from Biogen, Inc. (NASDAQ: BIIB), following the latter's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (formerly known as ALKS 8700), which is an oral fumarate in Phase-3 development for the treatment of relapsing forms of multiple sclerosis (MS). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alkermes and Biogen most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ALKS

www.active-investors.com/registration-sg/?symbol=BIIB

Alkermes to file NDA for BIIB098 to FDA in Q4 2018

Richard Pops, Chief Executive Officer (CEO) at Alkermes, stated that the clinical data generated from this program underscore the potential value of BIIB098 for patients with MS. Pops added that Alkermes' focus remains on completing the registration requirements and preparing the new drug application (NDA) for BIIB098 for submission to the US Food and Drug Administration (FDA) in the fourth quarter of the fiscal year 2018, as the Company advances this important potential new therapeutic option for patients with MS.

Terms of the License and Collaboration Agreement

  • Biogen has an exclusive, worldwide license to commercialize BIIB098 and will pay Alkermes a mid-teens percentage royalty on worldwide net sales.
  • Alkermes may also receive a $150 million milestone payment from Biogen upon the FDA's approval, on or before December 31, 2021, of the NDA for BIIB098.

Alkermes Plans to Seek Approval of BIIB098 Under the 505(b)(2) Regulatory Pathway

BIIB098 is currently in Phase-3 development for relapsing forms of MS. Alkermes plans to seek approval of BIIB098 under the 505(b)(2) regulatory pathway, referencing Biogen's TECFIDERA® (dimethyl fumarate). Alkermes' registration package for BIIB098 will include pharmacokinetic bridging studies to establish bioequivalence to dimethyl fumarate and data from a two-year safety study known as EVOLVE-MS-1, an open-label, two-year Phase-3 safety study of BIIB098 for the treatment of relapsing forms of MS.

Biogen and Alkermes Collaboration Deal for Development and Commercialization of ALKS 8700 for MS Treatment

In November 2017, both Companies inked a global license and collaboration agreement to develop and commercialize ALKS 8700 for the treatment of relapsing forms of MS. As per the agreement terms, Biogen received an exclusive, worldwide license to commercialize ALKS 8700 and paid Alkermes a mid-teens royalty on worldwide net sales of ALKS 8700. Biogen reimbursed Alkermes for 50% of the 2017 ALKS 8700 development costs, and Alkermes also received an upfront payment of $28 million representing Biogen's share of development expenses already incurred in 2017.

About Multiple Sclerosis (MS)

MS is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time.

About BIIB098

BIIB098 (diroximel fumarate) is an oral, novel fumarate candidate in development for the treatment of relapsing forms of MS. BIIB098 is designed to rapidly and efficiently convert to monomethyl fumarate (MMF) in the body and to potentially offer differentiated features compared to dimethyl fumarate.

About Alkermes PLC

Founded in 1987 and headquartered in Dublin, Ireland, Alkermes is a fully-integrated, global biopharmaceutical organization developing innovative medicines for the treatment of central nervous system (CNS) diseases. The Company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, and MS.

About Biogen Inc.

Headquartered in Cambridge, Massachusetts, Biogen is a biotechnology Company developing, marketing, and manufacturing therapies for people living with serious neurological, autoimmune, and rare diseases.

Stock Performance Snapshot

June 07, 2018 - At Thursday's closing bell, Alkermes' stock slightly fell 0.02%, ending the trading session at $48.30.

Volume traded for the day: 580.12 thousand shares.

Stock performance in the last month – up 9.30%

After yesterday's close, Alkermes' market cap was at $7.43 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

SOURCE:
Active-Investors